Leonard,
I am writing to confirm that Penterra Pharmaceuticals Corp. authorizes Calderwood & Harkness to accept the IRS Appeals settlement offer on the terms outlined below. Following a thorough review of the settlement offer analysis memorandum you and Sylvia prepared on March 18, together with the accompanying financial impact analysis workbook, I presented the proposed resolution to Catherine Falk and Rajesh Iyer earlier today. Management has approved acceptance, and Deborah Staines has independently reviewed the matter and is comfortable from a legal-authorization standpoint. Please proceed accordingly.
To confirm the terms we are authorizing you to accept:
- Total income adjustment of $47.6 million across TY 2017–2020, representing approximately 12.5% of the $380.4 million originally proposed by the examination team, allocated as follows: $11.2M (2017), $12.4M (2018), $12.8M (2019), and $11.2M (2020); - Federal tax due of approximately $10.0 million (at the 21% rate); - Estimated interest of approximately $2.84 million; - Full abatement of the IRC § 6662(e) substantial valuation misstatement penalty — this was an important outcome for us and one that management views very favorably; - Total estimated cash cost of approximately $12.84 million (tax plus interest); and - Resolution to be memorialized via Form 906 Closing Agreement.
Management views this resolution as highly favorable in light of our original exposure. The examination team's proposed adjustments would have resulted in approximately $79.9 million in federal tax plus $16.0 million in penalties — roughly $95.9 million before interest. Settling at approximately $12.84 million represents savings of over $83 million against the fully proposed amounts, and the complete elimination of the penalty is a significant result in its own right.
On the financial reporting side, I will be coordinating with Martin Ogilvy at Crestfield & Associates to adjust our FIN 48 / ASC 740-10 reserve position. Our pre-settlement reserve stood at $62.4 million, and we expect the post-settlement reserve to come down to approximately $14.8 million. Rajesh's team will need to assess the impact on PPC's upcoming financial statements and determine whether any SEC disclosure updates are required — Rajesh, I will set up time with you and your group early next week to walk through this.
One additional item: Deborah and I have reviewed the settlement amount against the tax-covenant provisions in the Hargrove National Bank revolving credit facility and do not believe the $12.84 million settlement triggers any material-tax-event or default provisions under the agreement. I recall that C&H prepared a covenant analysis memorandum on this point back in November 2023 — Leonard, could you confirm whether your earlier analysis reached the same conclusion? I want to make sure we are fully aligned before we close this out.
As for next steps, please proceed with formal written acceptance to Appeals Officer Noreen Castañeda at your earliest opportunity. I would appreciate your guidance on expected timing for negotiation and execution of the Form 906 Closing Agreement, as well as the mechanics for filing amended returns (Forms 1120X) for TY 2017–2020 and payment logistics for the tax and interest amounts. Separately, I will be looping in Ciarán Thornbury at Thornbury & Keogh to assess any Irish-side implications of the settlement for Penterra Biosciences Ireland.
Finally, I want to express my sincere thanks to you, Sylvia, and the full C&H team — including Elena Simmons and Arash Nazari — as well as Dr. Vasquez and the Whitmore Valuation Group for the extraordinary work over what has been a nearly two-year engagement. Settling at roughly 12.5% of the proposed adjustment with full penalty abatement is a result that speaks to the strength of the defense you assembled, particularly the functional analysis of PBI and the supporting economic analyses. This was a significant examination for Penterra, and the outcome reflects the quality of the effort.
Please let me know if you need anything further from our side to move forward with acceptance.
Best regards,
Marcus Whitfield Vice President, Global Tax Penterra Pharmaceuticals Corp. Direct: (215) 934-7182 mwhitfield@penterra.com